Hoth Therapeutics, Inc. (HOTH) Financial Statements
Industry: Pharmaceutical Preparations
Net income was -$12.5M, or -$0.90 per diluted share. Operating activities generated -$9.8M of cash. At fiscal year end, Hoth Therapeutics held $7.6M in total assets against $1.5M in total liabilities, including $6.2M of cash and equivalents.
Open the full interactive Hoth Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Hoth Therapeutics Key Stats
| Share Price | $0.57 |
|---|---|
| Market Cap | $11.7M |
| 52-Week Range | $0.51 – $2.22 |
| Shares Outstanding | 20.5 million (basic, 2026 Q2) |
Hoth Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — |
| Cost of Goods Sold | — | — | — | $29,000 | — | — |
| Gross Profit | — | — | — | -$29,000 | — | — |
| Operating Income | -$7.3M | -$14.1M | -$11.1M | -$7.7M | -$8.2M | -$12.4M |
| Pre-Tax Income | -$7.2M | -$14.3M | -$11.4M | -$7.8M | -$8.2M | -$12.5M |
| Net Income | -$7.2M | -$14.3M | -$11.4M | -$7.8M | -$8.2M | -$12.5M |
| Diluted EPS | -$14.50 | -$16.00 | -$8.79 | -$2.30 | -$1.28 | -$0.90 |
Hoth Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Net Income | -$4.1M | -$2.7M | -$2.7M | -$3.8M |
| Diluted EPS | -$0.30 | -$0.19 | -$0.17 | -$0.19 |
Hoth Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.6M | $8.5M | $6.4M | $9.3M | $7.0M | $6.2M |
| Current Assets | $4.8M | $10.6M | $6.7M | $9.4M | $7.6M | $6.9M |
| Total Assets | $5.2M | $11.0M | $6.8M | $9.5M | $7.7M | $7.6M |
| Current Liabilities | $312,149 | $867,787 | $1.4M | $678,657 | $831,197 | $1.5M |
| Total Liabilities | $597,149 | $1.1M | $1.6M | $704,983 | $833,906 | $1.5M |
| Shareholders' Equity | $4.6M | $9.9M | $5.1M | $8.8M | $6.9M | $6.2M |
Hoth Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$6.1M | -$12.1M | -$9.3M | -$8.4M | -$7.0M | -$9.8M |
| Cash From Investing | -$1.8M | -$165,355 | $1.2M | — | — | -$300,000 |
| Cash From Financing | $8.7M | $18.2M | $6.0M | $11.3M | $4.7M | $9.3M |
Figures from Hoth Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Hoth Therapeutics financials page for every line item.
Hoth Therapeutics Company Profile
| Ticker | HOTH |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Hoboken, New Jersey |
| Incorporated in | Nevada |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001711786 |
Frequently Asked Questions
What is Hoth Therapeutics' annual revenue history?
Hoth Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0.
What was Hoth Therapeutics' net income in fiscal 2025?
Hoth Therapeutics reported net income of -$12.5M for fiscal 2025.
What was Hoth Therapeutics' earnings per share (EPS) in fiscal 2025?
Hoth Therapeutics' diluted EPS was -$0.90 for fiscal 2025 (adjusted for any later stock splits).
How many shares of Hoth Therapeutics are outstanding?
Hoth Therapeutics reported a weighted average of 20.5 million basic shares outstanding in 2026 Q2.
What is Hoth Therapeutics' market cap?
Based on its latest closing price, Hoth Therapeutics (HOTH) has a market capitalization of about $11.7M.
When does Hoth Therapeutics' fiscal year end?
Hoth Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Hoth Therapeutics headquartered?
Hoth Therapeutics lists its business address in Hoboken, New Jersey in its SEC filings.